MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
Arcutis Biotherapeutics ROCE Ratio 2011-2025 | ARQT
Annual ROCE Ratio Arcutis Biotherapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.5 | -271.92 | -143.92 | -69.38 | -50.49 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -50.49 | -271.92 | -123.44 |
Quarterly ROCE Ratio Arcutis Biotherapeutics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -77.59 | -93.94 | -65.86 | -144.85 | -198.91 | -254.97 | -216.5 | -255.19 | -214.88 | -165.64 | -97.05 | -112.78 | -89.82 | -66.28 | -33.88 | -48.03 | -46.46 | -49.47 | -37.91 | -15.38 | 21.3 | 47.59 | 46.35 | 46.35 | 23.82 | 10.69 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.59 | -255.19 | -80.36 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.75 | -0.84 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-91.24 | $ 3.02 | -0.82 % | $ 233 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.28 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 208.81 | -1.88 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-517.39 | $ 0.59 | -36.2 % | $ 163 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
BioVie
BIVI
|
-95.03 | $ 1.23 | -3.54 % | $ 1.82 M | USA |
 |
Athersys
ATHX
|
-531.85 | - | 3.77 % | $ 22.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M | Britain |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 0.22 | 24.06 % | $ 479 M |  Israel |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 94.47 | -0.59 % | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
28.05 | $ 26.93 | 0.45 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-15.33 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 9.6 | 1.21 % | $ 141 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1339.01 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-125.56 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-1377.15 | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
2.51 | $ 584.75 | -1.08 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.49 | -1.78 % | $ 15.6 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | $ 92.62 | 0.18 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
424.75 | $ 12.33 | -0.32 % | $ 812 M | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
14.24 | $ 9.05 | 0.44 % | $ 1.48 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-26.11 | $ 26.29 | -2.01 % | $ 1.69 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 11.05 | 2.27 % | $ 715 M | USA |
 |
Cellectar Biosciences
CLRB
|
257.01 | $ 2.51 | -9.06 % | $ 30.7 M | USA |
 |
Biogen
BIIB
|
31.45 | $ 176.33 | - | $ 25.7 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-66.38 | - | - | $ 7.29 B | USA |